

Contents

PART I

1 Leukemia

Sue Zupanec • Deborah Tomlinson

1.1	Introduction	2
1.2	Acute Lymphoblastic Leukemia	3
1.2.1	Epidemiology	3
1.2.2	Etiology	4
1.2.3	Molecular Genetics	6
1.2.4	Symptoms and Clinical Signs	7
1.2.5	Diagnostics	8
1.2.6	Staging and Classification	9
1.2.7	Treatment	12
1.2.8	Prognosis	16
1.2.9	Follow-Up	16
1.2.10	Future Perspectives	17
1.2.11	Relapsed ALL	17
1.3	Acute Myeloid Leukemia	19
1.3.1	Epidemiology	19
1.3.2	Etiology	19
1.3.3	Molecular Genetics	20
1.3.4	Symptoms and Clinical Signs	20
1.3.5	Diagnostics	21
1.3.6	Staging and Classification	21
1.3.7	Treatment	22
1.3.8	Prognosis	24
1.3.9	Follow-Up	24
1.3.10	Future Perspectives	24
1.4	Chronic Myeloid Leukemia	25
1.4.1	Epidemiology and Etiology	25
1.4.2	Molecular Genetics	25
1.4.3	Symptoms and Clinical Signs	25
1.4.4	Diagnostics	26
1.4.5	Treatment	26
1.4.6	Prognosis	26
1.4.7	Future Perspectives	26
1.5	Juvenile Myelomonocytic Leukemia	26
1.6	Langerhans Cell Histiocytosis	27
1.6.1	Epidemiology and Etiology	27
1.6.2	Diagnostics	28
1.6.3	Symptoms and Clinical Signs	28
1.6.4	Treatment	29
1.6.5	Prognosis	29
References		29

2 Lymphoma

Sue Zupanec

2.1	Lymphoma	33
2.2	Hodgkin Lymphoma	33
2.2.1	Epidemiology	34
2.2.2	Etiology	34
2.2.3	Molecular Genetics	34
2.2.4	Symptoms and Clinical Signs	34
2.2.5	Diagnostics	36
2.2.6	Staging and Classification	38
2.2.7	Treatment	39
2.2.8	Prognosis	42
2.2.9	Follow-Up	43
2.2.10	Relapsed/Refractory HL	43
2.2.11	Future Perspectives	44
2.3	Non-Hodgkin Lymphomas	44
2.3.1	Epidemiology	44
2.3.2	Etiology	45
2.3.3	Molecular Genetics	45
2.3.4	Symptoms and Clinical Signs	46
2.3.5	Diagnostics	48
2.3.6	Staging and Classification	50
2.3.7	Treatment	50
2.3.8	Prognosis	54
2.3.9	Follow-Up	54
2.3.10	Treatment of Relapsed/Refractory NHL	55
2.3.11	Future Perspectives	55
References		56

3 Solid Tumor

Eleanor Hendershot

3.1	Ewing's Sarcoma Family of Tumors	60
3.1.1	Epidemiology	60
3.1.2	Etiology	60
3.1.3	Molecular Genetics	60
3.1.4	Symptoms and Clinical Signs	61
3.1.5	Diagnosis	61
3.1.6	Staging and Classification	63
3.1.7	Treatment	63
3.1.8	Prognosis	64

3.1.9	Follow-Up	65	3.6.9	Follow-Up	100
3.1.10	Future Perspectives	65	3.6.10	Future Directions.	100
3.2	Osteosarcoma	65	3.7	Rhabdomyosarcoma	100
3.2.1	Epidemiology	66	3.7.1	Epidemiology	100
3.2.2	Etiology.	66	3.7.2	Etiology.	101
3.2.3	Molecular Genetics.	66	3.7.3	Molecular Genetics.	101
3.2.4	Signs and Symptoms	67	3.7.4	Symptoms and Clinical Signs	101
3.2.5	Diagnostics	67	3.7.5	Diagnostics	101
3.2.6	Staging and Classification	68	3.7.6	Staging and Classification	103
3.2.7	Treatment	68	3.7.7	Treatment	103
3.2.8	Prognosis.	71	3.7.8	Prognosis.	106
3.2.9	Follow-Up	71	3.7.9	Follow-Up	106
3.2.10	Future Perspectives	71	3.7.10	Future Perspectives	106
3.3	Liver Tumors	72	3.8	Non-Rhabdomyosarcomatous	
3.3.1	Epidemiology	72		Soft-Tissue Sarcomas	107
3.3.2	Etiology.	72	3.8.1	Alveolar Soft-Part Sarcoma.	108
3.3.3	Molecular Genetics.	72	3.8.2	Desmoid Tumor (Aggressive	
3.3.4	Symptoms and Clinical Signs	72		Fibromatosis)	108
3.3.5	Diagnostics	73	3.8.3	Desmoplastic Small Round Cell Tumor	108
3.3.6	Staging and Classification	74	3.8.4	Infantile Fibrosarcoma	109
3.3.7	Treatment	75	3.8.5	Infantile Hemangiopericytoma	109
3.3.8	Prognosis.	76	3.8.6	Infantile Myofibromatosis	109
3.3.9	Follow-Up	76	3.8.7	Leiomyosarcoma	109
3.3.10	Future Perspectives	77	3.8.8	Liposarcoma.	109
3.4	Neuroblastoma	77	3.8.9	Malignant Peripheral Nerve	
3.4.1	Epidemiology	77		Sheath Tumor	110
3.4.2	Etiology.	77	3.8.10	Synovial Sarcoma	110
3.4.3	Molecular Genetics.	77	3.9	Germ Cell Tumors	110
3.4.4	Symptoms and Clinical Signs	79	3.9.1	Epidemiology	111
3.4.5	Diagnostics	80	3.9.2	Etiology.	111
3.4.6	Staging and Classification	81	3.9.3	Molecular Genetics.	112
3.4.7	Treatment	82	3.9.4	Symptoms and Clinical Signs	112
3.4.8	Prognosis.	85	3.9.5	Diagnostics	112
3.4.9	Follow-Up	85	3.9.6	Staging and Classification	113
3.4.10	Future Perspectives	86	3.9.7	Treatment	113
3.5	Renal Tumors.	86	3.9.8	Prognosis.	115
3.5.1	Epidemiology	86	3.9.9	Follow-Up	115
3.5.2	Etiology.	87	3.9.10	Future Perspectives	116
3.5.3	Molecular Genetics.	87	3.10	Rare Tumors	116
3.5.4	Symptoms and Clinical Signs	87	3.10.1	Adrenocortical Carcinoma	116
3.5.5	Diagnostics	88	3.10.2	Melanoma	117
3.5.6	Staging and Classification	89	3.10.3	Nasopharyngeal Carcinoma	118
3.5.7	Treatment	89	3.10.4	Pleuropulmonary Blastoma	118
3.5.8	Prognosis.	92	3.10.5	Thyroid Carcinoma.	119
3.5.9	Follow-Up	93	References	119	
3.5.10	Future Perspectives	93			
3.6	Retinoblastoma	93			
3.6.1	Epidemiology	93	4	Central Nervous System Tumors	
3.6.2	Etiology.	94		Nancy E. Kline • Joan O'Hanlon-Curry	
3.6.3	Molecular Genetics.	94	4.1	Causes/Epidemiology	129
3.6.4	Signs and Symptoms	94	4.2	Distribution/Classification	129
3.6.5	Diagnostics	95	4.3	Staging	130
3.6.6	Staging and Classification	96	4.4	Molecular Genetics of Brain Tumors	130
3.6.7	Treatment	96			
3.6.8	Prognosis.	99			

4.5	Diagnosis	130
4.6	Specialist Referral	130
4.7	Hydrocephalus	130
4.8	Treatment	131
4.8.1	Surgery	131
4.8.2	Radiotherapy	131
4.8.3	Chemotherapy	132
4.9	Prognosis	132
4.10	Specific Tumors	132
4.10.1	PNETs/Medulloblastomas	132
4.10.2	Astrocytomas/Glial Tumors	133
4.10.3	Malignant Gliomas	134
4.10.4	Other High-Grade Gliomas	134
4.11	Follow-Up	138
4.11.1	The Late Effects and Rehabilitation of Survivors	138
4.11.2	Palliative Care	139
4.11.3	Future Perspectives/New Innovations	139
References		140

PART II

5 Anemias

Rosalind Bryant

5.1	Anemia	142
5.2	Iron-Deficiency Anemia	146
5.2.1	Epidemiology	146
5.2.2	Etiology	146
5.2.3	Molecular Genetics	146
5.2.4	Symptoms/Clinical Signs	146
5.2.5	Diagnostic Testing	147
5.2.6	Treatment	148
5.2.7	Transfusion	148
5.2.8	Erythropoietin (Epogen)	148
5.2.9	Prognosis	149
5.3	Sickle Cell Disease	149
5.3.1	Epidemiology	149
5.3.2	Etiology	149
5.3.3	Molecular Genetics	149
5.3.4	Symptoms/Clinical Signs	149
5.3.5	Diagnostic Testing	150
5.3.6	Complications of SCD	151
5.3.7	Prognosis	158
5.3.8	Future Perspectives	158
5.4	Thalassemia	158
5.4.1	Alpha (α)-Thalassemia	158
5.4.2	Beta Thalassemia (Cooley Anemia)	159
5.4.3	Diagnostic Testing	160
5.4.4	Treatment	160
5.4.5	Treatment of Hemosiderosis (Iron Overload)	160
5.4.6	Chelation Therapy	161

5.4.7	Clinical Advances (Hemosiderosis)	161
5.4.8	Prognosis	161
5.4.9	Follow-Up	162
5.4.10	Future Perspectives	162
5.5	Hemolytic Anemia	162
5.5.1	Hereditary Spherocytosis	162
5.5.2	Autoimmune Hemolytic Anemia	164
5.5.3	Glucose-6-Phosphate Dehydrogenase Deficiency	165
5.6	Bone Marrow Failure Syndromes	167
5.6.1	Aplastic Anemia	167
References		170

6 Neutropenia

Karyn Brundige

6.1	Epidemiology	173
6.2	Etiology	174
6.3	Symptoms and Clinical Signs	175
6.4	Diagnostic Testing	175
6.5	Treatment	176
6.6	Prognosis	177
6.7	Follow-Up	178
References		178

7 Thrombocytopenia

Karyn Brundige

7.1	Epidemiology	179
7.2	Etiology	180
7.3	Symptoms and Clinical Signs	180
7.4	Diagnostic Testing	182
7.5	Treatment	182
7.6	Prognosis	184
7.7	Follow-Up	184
7.8	Future Perspectives	184
References		184

8 Bleeding Disorders

Joan O'Brien-Shea

8.1	Hemophilia	187
8.1.1	Epidemiology	187
8.1.2	Etiology	187
8.1.3	Genetics	188
8.1.4	Symptoms and Clinical Signs	188
8.1.5	Diagnostic Testing	190
8.1.6	Treatment	191
8.1.7	Prognosis	194
8.1.8	Follow-Up	194

8.1.9	Future Perspectives	194
8.2	von Willebrand Disease	194
8.2.1	Epidemiology	194
8.2.2	Etiology	195
8.2.3	Genetics	195
8.2.4	Symptoms and Clinical Signs	195
8.2.5	Diagnostic Testing	196
8.2.6	Treatment	199
8.2.7	Prognosis	200
8.2.8	Follow-Up	200
References		201

PART III

9 Chemotherapy

Christine Chordas • Kristen Graham

9.1	Introduction	204
9.2	Cancer Cell Characteristics	204
9.2.1	The Cell Cycle	204
9.2.2	Cell Cycle Control	205
9.3	Chemotherapy	206
9.3.1	Principles	206
9.3.2	Resistance	206
9.3.3	The Principles of Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics	206
9.3.4	Chemotherapy Techniques	207
9.4	Clinical Trials	207
9.4.1	Phase I Clinical Trials	208
9.4.2	Phase II Clinical Trials	208
9.4.3	Phase III Clinical Trials	208
9.4.4	Phase IV Clinical Trials	208
9.5	Chemotherapy Agents	208
9.5.1	Antimetabolites	211
9.5.2	Alkylating Agents	216
9.5.3	Antitumor Antibiotics	217
9.5.4	Anthracycline Antibiotics	218
9.5.5	Plant Derivatives	218
9.5.6	Antiangiogenic Agents	219
9.5.7	Miscellaneous Agents	220
9.6	Chemotherapy Protectants	221
9.6.1	Allopurinol (Zyloprim)	221
9.6.2	Amifostine (Ethylol)	221
9.6.3	Dexrazoxane (Zinecard)	221
9.6.4	Leucovorin Calcium (LCV, Wellcovorin, Citovorin Factor, Folic Acid)	221
9.6.5	Mesna (Mesnex)	221
9.6.6	Palifermin	222
9.7	Administration of Chemotherapy Agents	222
9.7.1	Preparation	222
9.7.2	Administration and Practice Considerations	223

9.8	Professional Guidelines to Minimize the Risk of Medication Errors	224
9.8.1	Prescribing Errors	224
9.9	Safe Practice Considerations	224
9.9.1	Mixing Chemotherapeutic Agents	225
9.9.2	Transporting Cytotoxic Agents	225
9.9.3	Safe Handling After Chemotherapy	225
9.9.4	Disposal of Cytotoxic Materials	225
9.9.5	Spill Management	226
9.9.6	Procedures Following Accidental Exposure	226
9.9.7	Storage	226
9.9.8	Medical Management	226
9.10	Administration of Chemotherapy in the Home	226
9.11	Immediate Complications of Chemotherapy Administration	226
9.11.1	Extravasation	227
9.11.2	Acute Hypersensitivity Reactions (HSRs) to Chemotherapy	230
9.11.3	Risk Factors for Hypersensitivity, Flare Reactions, or Anaphylaxis	230
9.11.4	Recommended Steps to Prevent HSRs	230
9.11.5	Emergency Management of HSR/Anaphylaxis	230
9.12	Summary	231
References		231

10 Radiotherapy

Irene Loch • Jane Khorrami

10.1	Introduction	233
10.2	Radiation	233
10.3	Principles of Treatment	234
10.4	Treatment Planning	234
10.4.1	CT Simulation	234
10.4.2	Simulation	234
10.5	Treatment Methods	235
10.5.1	External Beam Radiotherapy (Teletherapy)	235
10.5.2	Fractionation	237
10.5.3	Total Body Irradiation (TBI)	237
10.5.4	Brachytherapy	237
10.5.5	Sealed Sources	237
10.5.6	Unsealed Sources	237
10.6	Side Effects of Radiotherapy	238
10.6.1	Acute Effects	238
10.7	Special Considerations	240
10.7.1	Preparation of Children and Young People	240
10.8	Future Perspectives	240
10.8.1	Image-Guided Radiotherapy	240

10.8.2	Intra-Operative Radiotherapy	240
10.8.3	Proton Radiotherapy (PRT)	240
References		241

11 Hematopoietic Stem Cell Transplantation

Robbie Norville • Deborah Tomlinson

11.1	Principles of Treatment	243
11.2	Stem Cell Collection (Harvest)	244
11.2.1	Bone Marrow Stem Cells	244
11.2.2	Peripheral Blood Stem Cells	246
11.2.3	Umbilical Cord Blood Stem Cells	246
11.3	Donor Stem Cell Typing/ Tissue Typing	247
11.4	Donor Stem Cell Sources	248
11.5	Stem Cell Processing and Infusion	249
11.5.1	ABO Mismatch	249
11.5.2	Graft vs. Leukemia	251
11.6	Description of Treatment	251
11.7	Potential Side Effects	253
11.7.1	Early Side Effects	253
11.7.2	Intermediate Side Effects	257
11.7.3	Late Side Effects	261
11.8	Special Considerations	263
11.9	Future Perspectives	264
References		265

12 Surgical Approaches to Childhood Cancer

Carol L. Rossetto

12.1	Principles of Treatment	269
12.2	Method of Delivery	270
12.2.1	Preoperative Evaluation	270
12.2.2	Postoperative Nursing Care	271
12.3	Potential Side Effects	271
12.3.1	Complications of Medical Therapy Requiring Surgical Evaluation	271
12.3.2	Complications Arising from Surgical Management of Solid Tumors	272
12.4	Special Considerations	273
12.4.1	Vascular Access Devices	273
12.5	Future Perspectives	274
12.5.1	New Surgical Techniques and Directions for Future Research	274
References		275

13 Cell and Gene Therapy

Robbie Norville

13.1	Introduction	277
13.2	Principles of Treatment	278
13.2.1	Genetic Deficit Repair	278
13.2.2	Viral-Mediated Gene Transfer	278
13.2.3	Drug-Resistant Genes	278
13.2.4	Angiogenetics Inhibitors	279
13.2.5	Gene Marking	279
13.2.6	Cell Therapy	279
13.3	Method of Delivery	279
13.3.1	Viral Vectors	280
13.3.2	Plasmid Vectors	280
13.4	Potential Side Effects	280
13.5	Special Considerations	281
13.6	Future Perspectives	281
References		281

14 Biological and Targeted Therapies

Lindsay Gainer

14.1	Introduction	283
14.2	Principles of Treatment	284
14.3	Description of Treatment	285
14.3.1	Cytokines	285
14.3.2	Interferons	285
14.3.3	Interleukins	286
14.3.4	Colony-stimulating Factors	286
14.3.5	Fusion Proteins	286
14.3.6	Monoclonal Antibodies	287
14.4	Cancer Vaccines	288
14.5	Other Immunomodulating Agents	288
14.5.1	Nonspecific Immunomodulating Agents	288
14.5.2	Retinoids	289
14.5.3	Thalidomide	289
14.6	Adoptive Immunotherapy	289
14.7	Molecular Targeted Therapy	289
14.8	Method of Delivery	290
14.9	Potential Side Effects	291
14.10	Future Perspectives	292
References		293

15 Complementary and Alternative Medicine

Janice Post-White • Elena Ladas

15.1	Introduction	295
15.2	CAM Modalities	296

15.2.1	Acupuncture	296
15.2.2	Biological Therapies	297
15.2.3	Mind–Body Therapies	299
15.2.4	Movement Therapies	300
15.2.5	Aromatherapy	301
15.2.6	Massage	302
15.2.7	Energy Therapies	303
15.3	Future Perspectives	303
References		304

16 Clinical Trials

Biljana Dzolganovski

16.1	The Role of Clinical Trials	307
16.1.1	The Need for Research	307
16.1.2	Phases of Clinical Trials	308
16.1.3	Study Types	308
16.1.4	Research Ethics: Principles, Policies, and Guidelines	308
16.1.5	Legal and Ethical Issues Regarding Participation of Children in Research	310
16.1.6	Research in Pediatrics	312
16.2	Research Networks	312
16.2.1	Cooperative Group Research	312
16.2.2	Importance of Participation in Clinical Trials	314
16.3	Progress Made Through Clinical Trials	315
16.3.1	Treatments and Therapy Delivery	315
16.3.2	Quality of Life Measures and Supportive Care	319
16.3.3	Complementary and Alternative Medicine	320
16.3.4	Late Effects	321
16.3.5	Palliative Care	321
16.4	Perception of Clinical Trials	322
16.5	Future of Clinical Trials	324
16.6	The Role of the Clinical Research Associate	324
16.6.1	Introduction	324
16.6.2	Clinical Research Associate	325
16.6.3	The Role of the CRA	326
16.6.4	The Role of the Clinical Research Nurse	328
References		329

PART IV

17 Metabolic System

Deborah Tomlinson

17.1	Cancer Cachexia	337
17.1.1	Incidence	337
17.1.2	Etiology	338
17.1.3	Treatment	338

17.1.4	Prognosis	339
17.2	Obesity	339
17.2.1	Obesity in Survivors of Leukemia	339
17.3	Inferior Outcomes and Obesity	340
17.3.1	Incidence	340
17.3.2	Etiology	341
17.4	Tumor Lysis Syndrome	341
17.4.1	Incidence	341
17.4.2	Etiology	341
17.4.3	Treatment	343
17.4.4	Prognosis	347
17.5	Hypercalcemia	347
17.5.1	Incidence	347
17.5.2	Etiology	347
17.5.3	Treatment	347
17.5.4	Prognosis	348
17.6	Impaired Glucose Tolerance	348
17.6.1	Incidence	348
17.6.2	Etiology	348
17.6.3	Treatment	349
17.6.4	Prognosis	349
References		349

18 Gastrointestinal Tract

Anne Marie Maloney

18.1	Mucositis	354
18.1.1	Incidence	354
18.1.2	Etiology	354
18.1.3	Prevention	357
18.1.4	Treatment	357
18.1.5	Prognosis	358
18.2	Dental Caries	358
18.2.1	Incidence	358
18.2.2	Etiology	358
18.2.3	Prevention and Treatment	359
18.2.4	Prognosis	359
18.3	Nausea and Vomiting	359
18.3.1	Incidence	359
18.3.2	Etiology	359
18.3.3	Prevention	360
18.3.4	Treatment	360
18.3.5	Delayed Nausea and Vomiting	361
18.3.6	Anticipatory Nausea and Vomiting	361
18.3.7	Radiation-Induced Nausea and Vomiting	362
18.3.8	Other Causes of Nausea and Vomiting	363
18.3.9	Nonpharmacological Management	363
18.3.10	Prognosis	364
18.4	Constipation	364
18.4.1	Incidence	364
18.4.2	Etiology	364
18.4.3	Prevention	365
18.4.4	Treatment	365
18.4.5	Prognosis	366

18.5	Diarrhea	366
18.5.1	Incidence	366
18.5.2	Etiology	366
18.5.3	Prevention	368
18.5.4	Treatment	368
18.5.5	Prognosis	369
18.6	Typhylitis	369
18.6.1	Incidence	369
18.6.2	Etiology	370
18.6.3	Prevention	370
18.6.4	Treatment	370
18.6.5	Prognosis	371
18.7	Perirectal Cellulitis	371
18.7.1	Incidence	371
18.7.2	Etiology	371
18.7.3	Prevention	371
18.7.4	Treatment	371
18.7.5	Prognosis	372
18.8	Acute Gastrointestinal Graft Vs. Host Disease	372
18.8.1	Incidence	372
18.8.2	Prevention	372
18.8.3	Treatment	373
18.8.4	Prognosis	374
18.9	Chemical Hepatitis	374
18.9.1	Incidence	374
18.9.2	Etiology	374
18.9.3	Prevention	374
18.9.4	Treatment	374
18.9.5	Prognosis	375
18.10	Pancreatitis	375
18.10.1	Incidence	375
18.10.2	Etiology	375
18.10.3	Prevention	375
18.10.4	Treatment	375
18.10.5	Prognosis	375
References		376

19 Bone Marrow Function

Sandra Doyle

19.1	Introduction	380
19.2	Anemia	380
19.2.1	Incidence and Etiology	380
19.2.2	Treatment	380
19.3	Neutropenia	381
19.3.1	Incidence and Etiology	381
19.3.2	Treatment	382
19.4	Thrombocytopenia	389
19.4.1	Incidence and Etiology	389
19.4.2	Treatment	389
19.5	Transfusion Issues	390
19.5.1	Granulocyte Transfusions	390
19.5.2	Transfusion-Associated Graft vs. Host Disease	391

19.5.3	Cytomegalovirus and Transfusions	392
19.5.4	Platelet Refractoriness	392
19.6	Disseminated Intravascular Coagulation	393
19.6.1	Etiology and Manifestation	393
19.6.2	Treatment	394
19.7	Septic Shock	395
19.7.1	Etiology	395
19.7.2	Treatment	395
19.7.3	Prognosis	396
19.8	Immune Suppression	396
19.8.1	Polymorphonuclear Leukocytes	396
19.8.2	Lymphocytes	397
19.8.3	Spleen and Reticuloendothelial System	398
19.8.4	Other Factors Contributing to Immunocompromised States	398
References		398

20 Respiratory System

Margaret Parr

20.1	Pneumocystis Pneumonia	401
20.1.1	Incidence	401
20.1.2	Etiology	402
20.1.3	Treatment	402
20.1.4	Prognosis	404
20.2	Pneumonitis	404
20.2.1	Incidence	404
20.2.2	Etiology	404
20.2.3	Prevention	405
20.2.4	Treatment	405
20.2.5	Prognosis	405
20.3	Fibrosis	406
20.3.1	Incidence	406
20.3.2	Etiology	406
20.3.3	Prevention	406
20.3.4	Treatment	406
20.3.5	Prognosis	406
20.4	Compromised Airway	407
20.4.1	Incidence	407
20.4.2	Etiology	407
20.4.3	Prevention	407
20.4.4	Treatment	408
20.4.5	Prognosis	408
References		408

21 Renal System

Fiona Reid

21.1	Nephrectomy	412
21.1.1	Incidence	412
21.1.2	Etiology	412
21.1.3	Treatment	412
21.1.4	Prognosis	416

21.2 Cytotoxic Drug Excretion	417
21.2.1 Pharmacokinetics/Dynamics	417
21.2.2 Metabolism	418
21.2.3 Excretion	418
21.2.4 Drug Interactions	420
21.2.5 Dose Modification	420
21.2.6 Safe Handling of Cytotoxic Excreta	424
21.3 Nephrotoxicity	425
21.3.1 Incidence	425
21.3.2 Etiology	426
21.3.3 Prevention	427
21.3.4 Treatment	430
21.3.5 Prognosis	432
21.4 Hemorrhagic Cystitis	432
21.4.1 Incidence	432
21.4.2 Etiology	433
21.4.3 Prevention	434
21.4.4 Treatment	435
21.4.5 Prognosis	437
References	437

22 Cardiovascular System

Alison Hall

22.1 Cardiac Toxicity/Cardiomyopathy	441
22.1.1 Incidence	441
22.1.2 Etiology	443
22.1.3 Treatment	445
22.1.4 Prevention	445
22.1.5 Prognosis	447
22.2 Venous Occlusive Disease	447
22.2.1 Hepatic Venous Occlusive Disease	447
22.2.2 Pulmonary Venous Occlusive Disease	449
References	450

23 Central Nervous System

Jane Belmore • Deborah Tomlinson

23.1 Spinal Cord Compression	453
23.1.1 Incidence	453
23.1.2 Etiology	453
23.1.3 Treatment	454
23.1.4 Prognosis	454
23.2 Fatigue	454
23.2.1 Incidence	455
23.2.2 Etiology	455
23.2.3 Treatment	456
23.2.4 Prognosis	457
23.3 Cognitive Deficits	458
23.3.1 Incidence	458
23.3.2 Etiology	458

23.3.3 Prevention and Treatment	458
23.3.4 Prognosis	459
23.4 Diabetes Insipidus	459
23.4.1 Incidence	459
23.4.2 Etiology	460
23.4.3 Treatment	460
23.4.4 Prognosis	460
References	460

24 Musculoskeletal System

Deborah Tomlinson • Sue Zupanec

24.1 Bone Tumors	463
24.1.1 Limb Salvage Procedures	463
24.1.2 Amputation	464
24.1.3 Comparison of Limb Salvage and Amputation	469
24.2 Altered Bone Mineral Density and Increased Fracture Risk	470
24.2.1 Incidence	470
24.2.2 Etiology	471
24.2.3 Prevention and Treatment	471
24.2.4 Prognosis	472
24.3 Osteonecrosis	472
24.3.1 Incidence	473
24.3.2 Etiology	474
24.3.3 Treatment	474
24.3.4 Prognosis	475
References	475

25 Skin: Cutaneous Toxicities

Martina Nathan • Deborah Tomlinson

25.1 Alopecia	477
25.1.1 Etiology	477
25.1.3 Treatment	478
25.1.4 Prognosis	479
25.2 Altered Skin Integrity Associated with Radiation Therapy	479
25.2.1 Incidence	479
25.2.2 Etiology	479
25.2.3 Prevention	479
25.2.4 Treatment	480
25.2.5 Prognosis	481
25.3 Radiation Sensitivity and Recall	481
25.3.1 Incidence	481
25.3.2 Etiology	481
25.3.3 Clinical Features	481
25.3.4 Treatment	481
25.3.5 Prognosis	482
25.4 Ultraviolet Recall Reaction/Photosensitivity	482

25.5	Cutaneous Reactions Associated with High-Dose Cytosine Arabinoside	482
25.5.1	Incidence	482
25.5.2	Etiology	482
25.5.3	Prevention and Treatment	482
25.6	Nail Dystrophies	483
25.7	Graft Vs. Host Disease	483
25.7.1	Incidence and Etiology	483
25.7.2	Prevention	485
25.7.3	Treatment	486
25.7.4	Prognosis	486
References		486

26 Endocrine System

Julie Watson

26.1	Introduction	489
26.2	Hypothalamic–Pituitary Dysfunction	489
26.2.1	Incidence and Etiology	489
26.3	Growth Hormone Deficiency	491
26.3.1	Treatment	492
26.3.2	Prognosis	492
26.4	Hypothalamic–Pituitary–Gonadal Axis	493
26.4.1	Gonadotrophin Deficiency	493
26.4.2	Early or Precocious Puberty	493
26.5	Thyroid Disorders	494
26.5.1	Treatment	494
26.6	Hypothalamic–Pituitary–Adrenal Axis	495
26.6.1	Treatment	495
26.7	Other Pituitary Hormones	495
26.7.1	Fertility	496
26.7.2	Treatment	496
26.7.3	Prognosis	497
References		499

27 Ototoxicity

Colleen Nixon

27.1	Introduction	501
27.2	Prevention and Treatment	505
27.3	Future Perspectives	507
27.4	Prognosis	508
References		508

28 Ocular Complications

Martina Nathan • Deborah Tomlinson

28.1	Ocular Toxicity Associated with High-Dose Cytarabine Arabinoside	511
28.1.1	Incidence and Etiology	511

28.1.2	Prevention	512
28.1.3	Treatment	512
28.1.4	Prognosis	512
28.2	Cataracts	513
28.2.1	Incidence	513
28.2.2	Etiology	513
28.2.3	Prevention	513
28.2.4	Treatment	513
28.2.5	Prognosis	513
References		513

PART V

29 Nutrition and Hydration in Children with Cancer

Cheryl Rodgers • Sara Gonzalez

29.1	Introduction	515
29.2	Nutritional Assessment	516
29.2.1	Hydration Needs	516
29.2.2	Nutrition Needs	516
29.2.3	Nutritional History	517
29.2.4	Physical Examination	518
29.2.5	Anthropometric Measurements	518
29.2.6	Laboratory Evaluation	519
29.3	Principles of Treatment for Dehydration and Malnutrition	519
29.3.1	Rehydration	519
29.3.2	Oral Nutrition Replacement	520
29.3.3	Enteral Nutrition Replacement	520
29.3.4	Total Parenteral Nutrition/Hyperalimentation	521
29.4	Special Considerations	524
29.4.1	Common Hydration Complications	524
29.4.2	Common Complications of Oral/Enteral Nutritional Supplementation	524
29.4.3	Common Complications of Total Parenteral Nutrition/Hyperalimentation	525
29.4.4	Common Complications of Enteral and Parenteral Nutritional Supplementation	527
29.4.5	Specific Nutritional Concerns of Long-Term Survivors	527
29.4.6	Specific Nutritional Concerns During Palliative Care	527
References		528

30 Pain in Children with Cancer

Cara Simon

30.1	Introduction	529
30.2	Causes of Pain in Childhood Cancer	529

30.3	Assessment	530
30.4	Cultural Issues	536
30.5	Principles of Treatment	536
30.6	Treatment	537
30.6.1	By the Ladder	537
30.6.2	By the Route	538
30.6.3	By the Clock	538
30.6.4	Opioids	538
30.6.5	Equianalgesia	538
30.6.6	Procedure-Related Pain	540
30.6.7	Patient-Controlled Analgesia (PCA)	540
30.6.8	Adjuvant Medications	542
30.6.9	Nonpharmacologic Treatment	542
References		544

31 Blood Transfusion Therapy

Colleen Nixon

31.1	Introduction	546
31.2	Blood Screening Guidelines	546
31.3	Blood Product Processing	546
31.3.1	Irradiation	547
31.3.2	Washed Red Blood Cells	547
31.4	Transfusion Complications	547
31.4.1	Hemolytic Reactions	547
31.4.2	Febrile Nonhemolytic Transfusion Reactions	548
31.4.3	Allergic Reactions	548
31.4.4	Transfusion Associated Graft vs. Host Disease	549
31.4.5	Circulatory Overload	549
31.4.6	Bacterial Contamination	549
31.4.7	Transfusion-Acquired Infections	550
31.4.8	Iron Overload from Chronic Transfusion	551
31.5	Red Blood Cell Transfusion	551
31.5.1	Packed Red Blood Cells	551
31.5.2	Whole Blood	552
31.5.3	Exchange Transfusion	552
31.6	Platelet Transfusion	552
31.6.1	Indications	552
31.6.2	Procurement	553
31.6.3	Dosing/Transfusion Guidelines	553
31.6.4	Crossmatching	553
31.6.5	Nursing Implications	553
31.7	Granulocyte Transfusion	553
31.7.1	Indications	554
31.7.2	Dosing/Transfusion Guidelines	554
31.7.3	Crossmatching	554
31.7.4	Nursing Implications	554
31.8	Albumin (5 or 25% solution) and Plasma Protein Fraction (5% solution)	554
31.8.1	Indications	554

Contents

31.8.2	Dosing/Transfusion Guidelines	554
31.8.3	Crossmatching	555
31.8.4	Nursing Implications	555
31.9	Fresh Frozen Plasma	555
31.9.1	Indications	555
31.9.2	Dosing/Transfusion Guidelines	555
31.9.3	Crossmatching	555
31.9.4	Nursing Implications	555
31.10	Cryoprecipitate	555
31.10.1	Indications	555
31.10.2	Dosing Guidelines	556
31.10.3	Crossmatching	556
31.10.4	Nursing Implications	556
31.11	Intravenous Immunoglobulin	556
31.11.1	Indications	556
31.11.2	Dosing/Transfusion Guidelines	556
31.11.3	Crossmatching	556
31.11.4	Nursing Implications	556
31.12	Erythropoietin	556
31.13	Indications	557
31.14	Dosing Guidelines	557
31.15	Nursing Implications	557
31.16	Palliative Care Issues for Transfusion Therapy	557
31.16.1	Anemia and Thrombocytopenia	557
References		557

32 Cytokines

Linda D'Andrea

32.1	Principles of Treatment	559
32.2	Future Perspectives	563
References		564

33 Care of the Dying Child and the Family

Angela M. Ethier

33.1	Children's Understanding of Death	565
33.1.1	Infants (0–12 Months) and Toddlers (12–24 Months)	565
33.1.2	Preschool Children (3–5 Years)	566
33.1.3	School-Age Children (6–11 Years)	567
33.1.4	Adolescents (12–19 Years)	567
33.2	Explaining Death to Children	567
33.3	Pediatric Palliative Care	568
33.3.1	Principles	568
33.3.2	Locations of Care	568
33.4	Grief	569
33.4.1	Principles	569
33.4.2	Assessment of Child and Family	569
33.4.3	Interventions	571
33.5	Cultural and Spiritual Care	571

33.5.1 Principles 571

33.5.2 Assessment of Child and Family 571

33.5.3 Interventions 571

33.6 Nearing Death 573

33.6.1 Physical Symptoms Near the End of Life 573

33.6.2 Death-Related Sensory Experiences 574

33.7 Care Following the Child's Death 575

33.7.1 Interventions Immediately Following the
Child's Death 575

33.7.2 Bereavement Interventions 575

33.8 Resources 575

33.8.1 Resources for Children 575

33.8.2 Resources for Adults 576

References 576

Subject Index 579